Therefore, there is a need to develop alternative novel drug delivery formulations of albendazole to improve its intestinal absorption and also to reduce its side effects during regular therapy. The Albendazole nanoparticles were prepared by hot homogenization method under high magnetic stirring using stearic acid as lipid and poloxamer 188 was used as surfactant. Initial pre-formulation studies using FTIR spectroscopy reveals that there are no interactions between Albendazole and other excipients and hence they can be used for the preparation of nanoparticles. The entrapment efficiencies varied from a minimum of 43.56 ± 0.95 % to a maximum of 85.1 ±0.58% and it can be concluded that higher amount of lipid is necessary for obtaining a good entrapment efficiency. The drug content of albendazole nanoparticles for all formulation ranges from 65.8% to 98.1%. A spherical shape was observed for the particles and the particles had a smooth morphology when examined under SEM. In vitro release studies of the formulations carried out in pH 7.4 PBS showed that the total amount of drug is released for 9hrs with sustained effect. That the formulations showed a drastic increase in size when stored at room temperature where the size of particles increased from an initial to 343.7 ±7.9 nm at the end of 1 month to 898.1 ± 5.8 nm at the end of 2 months. Entrapment efficiency of the formulation was determined at each interval to ensure that the drug molecules didn't undergo any degradation during storage.
INTRODUCTION
Nanoparticles consist of a solid lipid matrix (at room and body temperatures) which are stabilized by surfactants and have a mean size of 50-1000 nm and stabilized by surfactants 1 . The main advantages of Nanoparticles are a controlled release of the drug can be achieved, The stability of the drug can be improved, high amounts of drug loading can be achieved, hydrophilic and lipophilic drugs can be incorporated there is no toxicity of the various lipids used of organic solvents can be prevented, Preparation of large scale of Nanoparticles can be easily scaled up for industrial purpose 2 . Nanoparticle are solid colloidal particles ranging from 10 to 1000 nm (1.0 μm), in which the active principles (drug or biologically active material) are dissolved, entrapped, and/or to which the active principle is adsorbed or attached 3 . In recent years, significant effort has been devoted to develop nanotechnology for drug delivery, since it offers a suitable means of delivering small molecular weight drugs, as well as macromolecules such as proteins, peptides or genes to cells and tissues and prevents them against enzymatic degradation 4 . Therefore, there is a need to develop alternative novel drug delivery formulations of albendazole to improve its intestinal absorption and also to reduce its side effects during regular therapy. Already, approaches like albendazole suspensions, liposome's and polymeric nanoparticles were developed to improve the efficacy 5 .
MATERIALS & METHODS
The Albendazole was purchased from Chimak Health Care, Himachal Pradesh, Excipients like Steric acid, Polaxamer 118 was procured from Sigma Aldrich chemicals Pvt. Ltd., USA, Bees wax, Dimethyl formamide, Sodium hydroxide, was procured from S.D. Fine Chem. Ltd. Mumbai. All other reagents used were of analytical grade.
Methodology:
FT-IR Studies: The purity of the drug was determined by subjecting Albendazole for IR analysis using Fourier Transform Infrared Spectroscopy (FT/IR 8400S (CE) Shimadzu spectrophotometer). The samples were prepared as KBr pellet method. Drug and potassium bromide are mixed in the ratio of 1:100 and a pellet is formed by compressing at 8 ton/mm 2 Scanning Electron Microscopy: The prepared Nanoparticle formulation was examined for surface morphology and shape using scanning electron microscope 8 . The scanning electron microscopy was performed on Hitachi high technologies corporation-S4800 type II, Japan. The samples were dried thoroughly in vacuum desiccators before mounting on brass specimen studies.
Particle Size: The average mean diameters and size distribution of albendazole loaded nanoparticles was found out by photon correlation spectroscopy using a Zeta sizer (nano ZS90, Malvern Instruments) at 25°C. The samples were kept in polystyrene cuvette and the readings were noted at a 90° fixed angle 9 .
Zeta Potential: The electrophoretic mobility (zeta potential) measurements of drug loaded nanoparticles were made using Zeta sizer (Nano ZS90, Malvern Instruments). The samples were placed in a polystyrene cuvette (at 25°C) and a Zeta dip cell was used to find out the potential 10 .
Entrapment Efficiency: 2ml of the formulation was taken and ultra-centrifuged at 13, 000 rpm at 4°C for 90 minutes using Eppendrof centrifuge 11 . The supernatant was recovered using micro pipette and analyzed by UV method for free drug content.
Drug content: 50mg of Albendazole nanoparticles was crushed and suspended in water to extract the drug from the nanoparticles. After 24 h, the filtrate was assayed spectrophotometrically at 295 nm for drug content against water as blank 12 .
In Vitro Release Studies: The in vitro release studies was carried out using in pH 7.4 phosphate buffer by dialysis bag method with a molecular weight cut off of 12,000-14,000 Da. Precisely 2 ml of the formulation was placed in the dialysis bag by sealing both the ends with the help of clips. The dialysis bag is dipped in a 50 ml dissolution medium maintained at 37± °C and stirred at 100 rpm using a magnetic stirrer. 2 ml of the buffer solution is removed at an interval of 1, 2, 3, 4, 6, 7, 8 and 10 hrs and is replaced by an equal amount of fresh buffer to maintain sink conditions 13 . The content of drug in the samples was determined by ultravisible spectroscopy at λmax of 295 nm.
Stability Studies as per ICH guidelines:
Stability of formulations during storage includes the preservation of initial particle size and prevention of degradation reactions. Stability studies were carried out for freeze dried method. The samples were stored in room temperature (25 to 30 °C) and in refrigerator (3 to 5 °C) over a period of 2 months. Samples were evaluated at 0, 1 and 2 months for their particle size, entrapment efficiency and changes in their physical appearance 14 .
RESULTS AND DISCUSSION
Drug excipients compatibility studies Formulation of albendazole nanoparticles: They were prepared by hot homogenization method under high speed magnetic stirring using stearic acid as lipid, Bees wax act as a wax and poloxamer 188 as surfactant. On a whole 8 formulations were prepared by changing the different ratios of lipids &Wax. The percentage of surfactant used ranging from 0.5, 0.75, 1.0 & 1.25%).
Determination of particle shape and surface morphology by using scanning electron microscopy: Scanning electron microscopy image revealed that the particles have a smooth texture and a spherical morphology as shown in figure 6 . 
Determination of zeta potential:
The Zeta potential of all the formulations varied between -0.04 ±1.6mV and -9.15 ±1.1 mV and is mentioned in table 3. Poloxamer being a nonionic surfactant was not able to induce potential on the surface of the nanoparticles and the partial negative observed was due to the charge induced by lipid and and drug. In Vitro drug release studies: In this section, the in vitro drug release studies have been carried out in pH 7.4 buffer (simulated intestinal pH) using a Dialysis bag which allows only the drug released from the nanoparticles to pass across the membrane. The drug solution was taken in the Dialysis bag which is placed in the buffer and samples are withdrawn at regular intervals of time for measuring drug concentration. All the formulations release till 10hrs which extend the therapeutic activity in the disease site. The release has followed biphasic pattern where 30-40% of the drug was released in first 1 hr and the remaining got released till 9 hrs. Stability Studies: Smaller particles tend to aggregate faster during transport, storage and dispersion. Stability studies were carried out on freeze dried at room temperature (20 -25°C) and refrigerator (3 to 5 °C) over a period of 2 months. Particle size, appearance of the formulation, drug release and FT-IR were evaluated to confirm the stability of the formulation. When stored at room temperature, the formulations showed instability by formation of larger floccules and when dispersed in water the solution turned into heavier particles. Whereas, the formulation when stored in refrigerated condition was stable with no visible floccules formation. Hence, it is concluded that the formulations should be stored in refrigerated conditions. When stored at room temperature where the size of particles increased from an initial to 343.7 ±7.9 nm at the end of 1 month to 898.1 ± 5.8 nm at the end of 2 months. The Entrapment Efficiency of formulation didn't show any change during the 60 days of storage in both refrigerated condition and room temperature. The entrapment efficiency is mentioned in table 8 & 9. 
Determination

SUMMARY & CONCLUSION
The present work was proposed to prepare and optimize Albendazole loaded Nanoparticle to improve its bioavailability and reduce its side effects which are caused when given conventionally. Initial pre-formulation studies using FTIR spectroscopy reveals that there are no interactions between Albendazole and other excipients and hence they can be used for the preparation of nanoparticles. Albendazole nanoparticles were prepared by hot homogenization method under high magnetic stirring using stearic acid as lipid and poloxamer 188 was used as surfactant. On whole 8 batches of formulations were prepared by varying the amount of lipid and surfactant and were evaluated for various parameters like particle size, shape, morphology, physical state, entrapment efficiency, Drug content and in vitro drug release. Particle size was measured using Malvern Zeta sizer and the size range of the particles was found to be in the range of 110.6 ±1.5 nm to 400.9 ± 2.4nm. Increase in size of nanoparticles was observed when we gradually increase the lipid content. The different concentrations of surfactant were evaluated for optimum one required for the preparation of stabilized solid lipid nanoparticles. The entrapment efficiencies varied from a minimum of 43.56 ± 0.95 % to a maximum of 85.1 ±0.58% and it can be concluded that higher amount of lipid is necessary for obtaining a good entrapment efficiency. The drug content of albendazole nanoparticles for all formulation ranges from 65.8% to 98.1%. Albendazole, being a hydrophobic drug has moderate entrapment efficiency. A spherical shape was observed for the particles and the particles had a smooth morphology when examined under SEM. In vitro release studies of the formulations carried out in pH 7.4 PBS showed that the total amount of drug is released for 9hrs with sustained effect. Taking the particle size, entrapment efficiency and in vitro release into account F4 was found out to be the best formulation which has a particle size of 249 ± 0.59 nm and entrapment efficiency of 85.1 ±0.58%. The drug content was release from 98.1%. Further, F4 is one among the few formulations which showed a drug release up to 9hrs, perform with release order kinetics like zero order, first order, Higuchi matrix, korsmeyer peppas it must best fit the model was zero order kinetics. The stability studies are performed with appearance of the formulation will stored at room temperature, the formulations showed instability by formation of larger floccules and when dispersed in water the solution turned into heavier particles. Whereas, the formulation when stored in refrigerated condition was stable with no visible floccules formation. The particle size of the formulation is evaluated by photon correlation spectroscopy and the particle size. That the formulations showed a drastic increase in size when stored at room temperature where the size of particles increased from an initial to 343.7 ±7.9 nm at the end of 1 month to 898.1 ± 5.8 nm at the end of 2 months. Entrapment efficiency of the formulation was determined at each interval to ensure that the drug molecules didn't undergo any degradation during storage.
